date:Aug 21, 2012
) or placebo for 24 weeks.
Results showed that anthocyanin supplementation was associated with a 22% reduction in CRP levels, compared to only 2.5% in the placebo group. In addition, the anthocyanins were linked to a 12.3% reduction in sVCAM-1 levels, compared to 0.4% in the placebo group.
Levels of interleukin-1beta (IL-1beta) also decreased in the anthocyanin group by 12.8%, compared to only 1.3% in the placebo group.
Cholesterol improvements were also observed for participants of the antho